Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design.
Jaclyn CarberryMark C PetrieMatthew M Y LeeKatriona BrooksbankRoss T CampbellRichard GoodPardeep S JhundPeter KellmanNinian N LangKenneth MangionPatrick B MarkAlex McConnachieJohn J V McMurrayBarbara MeyerVanessa OrchardAadil ShaukatStuart WatkinsPaul WelshNaveed SattarColin BerryKieran F DochertyPublished in: ESC heart failure (2024)
EMPRESS-MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with left ventricular systolic dysfunction after an acute MI.
Keyphrases
- left ventricular
- heart failure
- hypertrophic cardiomyopathy
- cardiac resynchronization therapy
- liver failure
- acute myocardial infarction
- multiple sclerosis
- aortic stenosis
- mitral valve
- left atrial
- blood pressure
- respiratory failure
- drug induced
- aortic dissection
- hepatitis b virus
- adverse drug
- aortic valve
- percutaneous coronary intervention
- acute respiratory distress syndrome
- ejection fraction
- mechanical ventilation